GHK-Cu: What the Research Says

What GHK-Cu Is

GHK-Cu is a complex formed between the naturally occurring human tripeptide glycyl-L-histidyl-L-lysine (Gly-His-Lys) and a divalent copper ion. The peptide was first isolated in 1973 by Loren Pickart from the albumin fraction of human plasma, during work investigating why plasma from young donors maintained liver tissue better than plasma from older donors. The central histidine residue binds Cu(II) with high affinity, which effectively turns the tripeptide into a physiological copper shuttle between the extracellular matrix and the cell.

GHK is present in plasma, saliva and urine, and the concentrations summarised by Pickart and Margolina decline substantially with age — from roughly 200 ng/mL in people in their twenties to around a third of that above sixty. That age curve is the reason the compound has been studied in the context of wound healing, skin remodelling and regenerative biology. Browse the full peptides category to see where GHK-Cu sits among the other research compounds we carry.

Key Research Findings

1. Wound healing and matrix synthesis. The early animal work of Maquart and colleagues in the late 1980s and early 1990s showed that GHK-Cu applied to experimental wounds in rat and rabbit models accelerated wound contraction and increased the accumulation of collagen and glycosaminoglycans. Siméon and co-workers extended this line in vitro, documenting stimulation of type I collagen, decorin and elastin synthesis by dermal fibroblasts.

2. Remodelling, not just deposition. Several studies report a simultaneous increase in matrix metalloproteinases (notably MMP-2) and in their tissue inhibitors (TIMP-1, TIMP-2). This bidirectional effect is interpreted as genuine remodelling — degradation of damaged matrix alongside synthesis of new matrix — rather than simple collagen accumulation.

3. Gene expression modulation. Pickart’s 2015 review in BioMed Research International, and the follow-up review by Pickart and Margolina in the International Journal of Molecular Sciences in 2018, summarise analyses of public gene-expression databases suggesting that micromolar GHK shifts the expression of a substantial proportion of assayed human genes, including genes involved in DNA repair, antioxidant defence and inflammation. The important qualification is that these are bioinformatic and cell-culture observations, not clinical endpoints.

4. Anti-inflammatory signals in cell models. Gruchlik and colleagues reported that the copper complex of GHK reduced TNF-α-induced IL-6 secretion in normal human dermal fibroblasts, and raised the question of whether such peptides might serve as an alternative to topical corticosteroids in inflammatory skin conditions. That remains a hypothesis; it has not been tested in controlled clinical trials.

5. Cosmetic clinical observations. A number of small clinical series using topical copper-peptide formulations — including the work of Leyden and of Finkey and colleagues reported at dermatology meetings in the early 2000s — describe improvements in skin density, fine lines and laxity. These studies are small, frequently sponsored by the manufacturers of the formulations being tested, and are not a substitute for independent randomised trials.

Safety Profile in the Research

Applied topically at cosmetic concentrations, GHK-Cu is generally described as well tolerated; the reported effects are mostly transient erythema or irritation, with occasional contact hypersensitivity to copper. Systemic administration in humans, by contrast, has no controlled safety dataset behind it. Copper is an essential trace element with a relatively narrow physiological window — both deficiency and accumulation carry toxicological weight — which makes total copper burden a substantive rather than a formal question. A separate practical issue is raw-material quality: the peptide-to-copper ratio, free copper ion content and residual solvent levels vary between batches, which is why the certificates of analysis in our lab testing section are worth reading before any work begins.

Open Questions

First, almost all of the persuasive literature is topical or cell-based; whether the observations translate to systemic exposure has not been established. Second, the optimal chemical form — free peptide, 1:1 copper complex, or stabilised derivatives — remains contested, as does how much active material crosses the stratum corneum at all. Third, the gene-expression ‘rejuvenation’ signatures are correlative and have not been shown to produce functional outcomes in humans. Fourth, large, independent, long-term trials with pre-registered endpoints simply do not exist. For preparing laboratory solutions, our peptide calculator may be useful, and for a different angle on ageing biology see our summary of NAD+. The research material discussed here is GHK-Cu (Skin Glow) 100 mg.

Specification

Disclaimer: This article is a summary of published scientific literature, provided for research and educational purposes only. PeptaMED supplies all materials strictly for laboratory research use only. They are not medicinal products, food supplements or cosmetics, and they are not intended for human or veterinary consumption, nor for the diagnosis, treatment or prevention of any disease. No human dosing information is given here and no use is recommended. Consult a qualified healthcare professional for any health-related question.

Products mentioned in this article

GHK-Cu (Skin Glow) | 100 mg | Dosing Pen€62,00View product →